Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 15/20 | 0.57 |
| ▸ | RARG | P13631 | 14/20 | 0.57 |
| ▸ | RARA | P10276 | 13/20 | 0.57 |
| ▸ | RXRA | P19793 | 10/20 | 0.55 |
| ▸ | RXRB | P28702 | 6/20 | 0.49 |
| ▸ | RXRG | P48443 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8703828 | 0.86 | RARA (0.57) | RARBRARGRARARXRARXRB | |
| SCHEMBL8703841 | 0.86 | RARA (0.57) | RARBRARGRARARXRARXRB | |
| SCHEMBL8704769 | 0.83 | RXRA (0.71) | RARBRARGRARARXRARXRB | |
| SCHEMBL8704037 | 0.82 | RARA (0.51) | RARBRARGRARARXRARXRB | |
| SCHEMBL8101908 | 0.81 | RARB (0.72) | RARBRARGRARARXRARXRB | |
| SCHEMBL9185721 | 0.80 | RARA (0.53) | RARBRARGRARARXRACYP3A4 | |
| Terephthalic Acid SCHEMBL27259373 | 0.77 | RARB (0.60) | RARBRARGRARARXRARXRB | |
| SCHEMBL9186843 | 0.77 | RARA (0.47) | RARBRARGRARARXRARXRB | |
| SCHEMBL10565430 | 0.76 | RARB (0.70) | RARBRARGRARARXRARXRB | |
| SCHEMBL3456673 | 0.76 | RARB (0.64) | RARBRARGRARARXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6627652-B1 | Treatment of diseases or conditions of the type which are normally treated with retinoid-like compounds is disclosed, with pharmaceutical compositions containing an active compound which is a selective agonist of the RXR retinoid | ALLERGAN, INC. | 2003-09-30 | — | — | US | disclosed |
| US-6624188-B1 | Administered to treat or prevent one or more of the diseases and conditions selected from the group consisting of dermatoses, atherosclerosis and restenosis resulting from neointimal hyperproliferation, non-malignant and | ALLERGAN, INC. | 2003-09-23 | — | — | US | disclosed |
| US-5324840-A | Skin disorders | ALLERGAN, INC. (US) | 1994-06-28 | — | — | US | disclosed |